Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Marks

Showing results (531-540 of 683) with videos related to

Pageof 69
Sort By:
British Journal of Haematology|July 11, 2006
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation studyJennifer M Bird, Rhian Fuge, Bhawna Sirohi, et al.
Bone Marrow Transplantation|June 22, 2005
Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletionR J Garland, S J Groves, P Diamanti, et al.
American Journal of Hematology|July 29, 2016
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXIIAnita J Kumar, Phyllis A Gimotty, Joel M Gelfand, et al.
The Lancet. Haematology|March 31, 2022
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trialDavid I Marks, Laura Clifton-Hadley, Mhairi Copland, et al.
Haematologica|November 28, 2015
Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donorsEsteban Arrieta-Bolaños, Neema P Mayor, Steven G E Marsh, et al.
Cancer|November 24, 2020
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemiaWendy Stock, Giovanni Martinelli, Matthias Stelljes, et al.
British Journal of Haematology|May 27, 2005
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myelomaNicolaus Kröger, Bronwen Shaw, Simona Iacobelli, et al.
Haematologica|September 24, 2013
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donorsDavid I Marks, Kwang Ahn Woo, Xiaobo Zhong, et al.
The New England Journal of Medicine|November 27, 2004
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemiaMary J Laughlin, Mary Eapen, Pablo Rubinstein, et al.
Blood|November 27, 2013
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaAdele K Fielding, Jacob M Rowe, Georgina Buck, et al.
Pageof 69

Showing results (531-540 of 683) with videos related to

Sort By:
Pageof 69
British Journal of Haematology|July 11, 2006
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation studyJennifer M Bird, Rhian Fuge, Bhawna Sirohi, et al.
Bone Marrow Transplantation|June 22, 2005
Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletionR J Garland, S J Groves, P Diamanti, et al.
American Journal of Hematology|July 29, 2016
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXIIAnita J Kumar, Phyllis A Gimotty, Joel M Gelfand, et al.
The Lancet. Haematology|March 31, 2022
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trialDavid I Marks, Laura Clifton-Hadley, Mhairi Copland, et al.
Haematologica|November 28, 2015
Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donorsEsteban Arrieta-Bolaños, Neema P Mayor, Steven G E Marsh, et al.
Cancer|November 24, 2020
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemiaWendy Stock, Giovanni Martinelli, Matthias Stelljes, et al.
British Journal of Haematology|May 27, 2005
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myelomaNicolaus Kröger, Bronwen Shaw, Simona Iacobelli, et al.
Haematologica|September 24, 2013
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donorsDavid I Marks, Kwang Ahn Woo, Xiaobo Zhong, et al.
The New England Journal of Medicine|November 27, 2004
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemiaMary J Laughlin, Mary Eapen, Pablo Rubinstein, et al.
Blood|November 27, 2013
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaAdele K Fielding, Jacob M Rowe, Georgina Buck, et al.
Pageof 69